Michael Davidson to Antineoplastic Agents
This is a "connection" page, showing publications Michael Davidson has written about Antineoplastic Agents.
Connection Strength
0.126
-
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004 Apr 15; 116(8):546-54.
Score: 0.097
-
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut. 2018 10; 67(10):1780-1792.
Score: 0.015
-
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol. 2016 Feb; 77(2):375-83.
Score: 0.014